Lineage Cell Therapeutics, Inc.LCTXNYSE
Loading
Year-over-year operating cash flow growth rate
Latest
-34.90%
↓ 521% vs avg
Percentile
P13
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
8.30%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -34.90% |
| Q3 2025 | 34.72% |
| Q2 2025 | -13.36% |
| Q1 2025 | 23.01% |
| Q4 2024 | -9.66% |
| Q3 2024 | -11.80% |
| Q2 2024 | 10.50% |
| Q1 2024 | 3.92% |
| Q4 2023 | -19.50% |
| Q3 2023 | 19.64% |
| Q2 2023 | 44.24% |
| Q1 2023 | -35.40% |
| Q4 2022 | -51.51% |
| Q3 2022 | 22.40% |
| Q2 2022 | -132.24% |
| Q1 2022 | 472.96% |
| Q4 2021 | -21.14% |
| Q3 2021 | 10.49% |
| Q2 2021 | 27.05% |
| Q1 2021 | -31.61% |
| Q4 2020 | -16.38% |
| Q3 2020 | -14.34% |
| Q2 2020 | 15.66% |
| Q1 2020 | 9.00% |
| Q4 2019 | 25.80% |
| Q3 2019 | 23.01% |
| Q2 2019 | -3.79% |
| Q1 2019 | -60.25% |
| Q4 2018 | 20.73% |
| Q3 2018 | 0.92% |
| Q2 2018 | 28.42% |
| Q1 2018 | -82.17% |
| Q4 2017 | 26.12% |
| Q3 2017 | 15.25% |
| Q2 2017 | -11.92% |
| Q1 2017 | 8.52% |
| Q4 2016 | 0.71% |
| Q3 2016 | 12.99% |
| Q2 2016 | 28.41% |
| Q1 2016 | -2.62% |